ストックスクリーナーアプリを入手
13.81
2.14%
0.29
アフターアワーズ：
13.81
Bioventus Inc (BVS) 最新ニュース
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Bioventus Inc. (NASDAQ: BVS) - Lelezard
Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS) - Seeking Alpha
Bioventus Stock Price Forecast. Should You Buy BVS? - StockInvest.us
Bioventus Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-03-05 - Seeking Alpha
Bioventus Inc. (BVS) Stock Analysis: Exploring a Potential 39% Upside in the Healthcare Sector - DirectorsTalk Interviews
Bioventus Inc (BVS) Shares Fall 4.3% -- What GF Score of 53 Tells Investors - GuruFocus
Bioventus Inc. (BVS) Slides 4.32% to $12.63 as Shares Pull Back Toward Key SupportDefined Outcome ETF - dars.gov.et
Bioventus Inc. (BVS) Edges Higher as Stock Tests Resistance Near $13.86Momentum Surge Alerts - siam.in
Bioventus Inc. Stock Price Prediction: Today, Tomorrow, Next Week (BVS) - Traders Union
Bank of New York Mellon Corp Takes Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Retreats 2.90% to $13.23, Testing Key Support ZonePut Call Ratio - dars.gov.et
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Bioventus (NASDAQ:BVS) Gains As Healthcare Demand Supports Growth - Kalkine Media
Bioventus Inc. (NASDAQ:BVS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Bioventus Inc (BVS) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 58/100 - GuruFocus
Bioventus Inc. Class A (BVS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BIOVENTUS INC. (BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of The Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (BVS) - TMX Newsfile
Bioventus Inc. (BVS) Holds Steady Near $13.84 as Investors Weigh Support and ResistanceExhaustion Gap - siam.in
Bioventus Inc. Class A (BVS) Peer Comparison – Compare with Others - Value Research
Are Investors Undervaluing Bioventus (BVS) Right Now? - qz.com
Globeflex Capital L P Purchases New Shares in Bioventus Inc. $BVS - marketbeat.com
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS) - easternprogress.com
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth - Eastern Progress
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? - Eastern Progress
Can Bioventus (NASDAQ:BVS) Keep Its Momentum Going? - Kalkine Media
BVS Maintains Buy Rating by Canaccord Genuity -- Price Target Ra - GuruFocus
BVS Reiterated by Cantor Fitzgerald -- Price Target Maintained a - GuruFocus
Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
CCORF Initiates Bioventus(BVS.US) With Buy Rating, Announces Target Price $19 - Moomoo
Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
(BVS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bioventus (BVS) Q2 2026 Earnings Call Transcript - The Globe and Mail
Dimensional Fund Advisors LP Increases Position in Bioventus Inc. $BVS - MarketBeat
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance
Bioventus (NASDAQ:BVS) Gains Attention After Strong Quarterly Update - Kalkine Media
Sei Investments Co. Boosts Holdings in Bioventus Inc. $BVS - MarketBeat
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Bioventus (BVS) Is Up 6.1% After Reaffirming 2026 Sales Outlook And Strong Q2 Earnings Jump - Sahm
Bioventus Inc. (BVS) Stock Analysis: Healthcare Innovator With 5.87% Upside Potential - DirectorsTalk Interviews
Bioventus Inc (BVS) Stock News Today - TradingKey
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Bioventus Inc. $BVS Shares Sold by Renaissance Technologies LLC - MarketBeat
Latham & Watkins Advises Bioventus in Review of Strategic Alternatives - Latham & Watkins LLP
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Bioventus Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Bioventus (BVS) Drops 8.9% to $13.9: Key Support Tested After Sharp SelloffIV Percentile - dars.gov.et
Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain - simplywall.st
Bioventus earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Bioventus Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BVS) 2026-08-05 - Seeking Alpha
Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ... - Yahoo Finance
Earnings call transcript: Bioventus posts Q2 2026 EPS beat, shares slip premarket - Investing.com Nigeria
Bioventus (NASDAQ:BVS) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bioventus Inc. Q2 2026 Earnings: Strong Revenue Growth, Net Income, and Financial Highlights - Minichart
Bioventus Shareholder Action Reminder - TMX Newsfile
Bioventus Inc. Reports Q2 2026 Results and Strategic Review in Latest 10-Q Filing - Kalkine Media
Bioventus Q2 Earnings Call Highlights - MarketBeat
Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed - marketscreener.com
1.51%
0.97%
大文字化:
|
ボリューム (24 時間):